Lung cancer: Drug with unique disruption of tumor blood flow shows promise
Monday, January 18, 2010 - 00:28
in Health & Medicine
Phase II study results of the agent ASA404 showed promise in patients with either squamous or non-squamous non-small cell lung cancer.